RXi Pharmaceuticals and the Center for Cancer Immune Therapy at Herlev Hospital Announce Research Collaboration
Saturday, December 02, 2017
RXi Pharmaceuticals Corporation a clinical-stage company developing a new class of RNAi-based therapeutics and the Center for Cancer Immune Therapy (CCIT) at Herlev Hospital, a leading European center for use of tumor infiltrating lymphocytes (TIL) for adoptive T-cell therapy (ACT), today announced that they have entered into a collaborative research agreement to evaluate the potential of RXi's novel self-delivering RNAi (sd-rxRNA®) technology platform in TILs for the use in treatment for a number of cancer types, including melanoma and ovarian cancer.
Dr. Karen Bulock, Vice President of Research at RXi Pharmaceuticals said, "Immunotherapy treatments have shown significant promise in extending the lifespan of previously untreatable cancer patients. We are excited to work with the extraordinary scientific leaders at the CCIT to evaluate the advantages of our therapeutic sd-rxRNA compounds in various cancer models." She further added that, "This research collaboration, in combination with other collaborations we have announced, are going to be key cornerstones in our efforts to translate positive results into a clinical setting which we hope to achieve within the next 12-18 months."
Professor and Director at CCIT, Inge Marie Svane, MD, Ph.D., said that, "Over the course of the last few years, the CCIT has carried out numerous clinical trials based on a direct translation of the discoveries from the laboratory. We are excited to test the potential of RXi's innovative self-delivering RNAi technology platform to potentiate TILs for ACT."
